HIGHLIGHTS
- who: Kamlesh Khunti from the Diabetes Research Centre, University of Leicester, Leicester, UK have published the article: Diabetes and the COVID-19 pandemic, in the Journal: (JOURNAL)
- what: This study showed dapagliflozin was well tolerated and numerically resulted in fewer events of organ dysfunction but no statistically significant difference in the dual primary outcome of prevention (time to new or worsening organ dysfunction or death), or the hierarchical composite outcome of recovery by 30 days.
- how: This review discusses the current literature to answer three fundamental questions what is the impact of acute . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.